Optimising new techniques for the early detection of lung cancer and improving the treatment of malignant pleural mesothelioma.
Description: Analysis of VOC’s for early detection of lung cancer. Lung cancer is often diagnosed at a late-stage and has a poor prognosis (5-year survival rate: 17%). Survival rate is about 76 to 90% when LC is detected at an early-stage.LCC screening is therefore a major public health concern.In the near future, LC screening will be carried out by low-dose radiation chest scanner (LDCT-scan). VOCs analysis in exhaled breath, using an electronic nose, has the potential to be a non-invasive diagnostic test. The challenge is to optimise the electronic nose prototype for it to be ready for tests performed under clinical settings. 3 goals: Make the electronic nose prototype suitable for use in hospital settings Evaluate electronic nose ability to discriminate LC patients from control population future integration of the electronic nose in LC screening programmes Immunotherapy in mesothelioma (rare disease) understanding the pathological changes after immunotherapy resistance mechanisms on immunotherapy
Funder: Vlaamse regering
Funding type: grant
Funder scheme: BOF - projects
Start date: 2024-01-01
End date: 2025-12-31
Investigator: Veerle Surmont (lead)
Institutions: Ghent University, UGent
Subfield: Biomedical Engineering
Field: Engineering
Domain: Physical Sciences
Funded outputs count: 0
Funder award ID: bof/baf/4y/24/1/1115
OpenAlex ID: G3986130415